Avid-45 in frontotemporal dementia, Alzheimer's and normal controls

• Research type

  Research Study

• Full title

  A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer’s disease and normal controls

• IRAS ID

  4459

• Sponsor organisation

  Avid Radiopharmaceuticals, Inc.

• Eudract number

  2008-003597-18

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  18F-AV-45 is a new agent that will allow doctors to look at changes in the brain of patients with Alzheimer's disease using a Positron Emission Tomography (PET) scanner. It is radioactively labelled by the short-living isotopflurine-18 (18F) and is injected intravenously in minute amounts prior to performing the imaging procedure. This PET tracer technique visualises a chemical, called amyloid-×ý peptide, that builds up in the brain of a patient with Alzheimer's disease. These deposits are called amyloid plaques and are a diagnostic hallmark of Alzheimer's disease in brain tissue. Until recently they could by detected only after patients' death at autopsy but not by diagnostic procedures during lifetime. 18F-AV-45 is expected to detect amyloid deposition in living patients with Alzheimer's disease and to distinguish them from patients with non-Alzheimer's disease related dementias. In this study, 10 healthy volunteers and 30 patients with either Alzheimer's disease or Fronto-temporal dementia (FTD), a dementia not associated with deposition of amyloid-×ý peptide, will be studied in order to look at the amount of accumulation of 18F-AV-45 in PET scans and to validate the utility of this tracer to distinguish between Alzheimer??s and non-Alzheimer??s disease.

• REC name

  North East - Newcastle & North Tyneside 2 Research Ethics Committee

• REC reference

  08/H0907/158

• Date of REC Opinion

  1 Apr 2009

• REC opinion

  Further Information Favourable Opinion